Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aquestive Therapeutics Inc (NQ: AQST )

2.470 +0.080 (+3.35%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 4, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,068,324
Open 2.470
Bid (Size) 2.400 (6)
Ask (Size) 2.550 (6)
Prev. Close 2.390
Today's Range 2.351 - 2.670
52wk Range 0.7200 - 2.690
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Where Aquestive Therapeutics Stands With Analysts
Via Benzinga

Performance

YTD
+174.47%
+174.47%
1 Month
+54.38%
+54.38%
3 Month
+49.70%
+49.70%
6 Month
+14.35%
+14.35%
1 Year
+171.40%
+171.40%

More News

Read More
Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 6, 2023
Via Benzinga
Preview: Aquestive Therapeutics's Earnings
Via Benzinga
Earnings Outlook For Aquestive Therapeutics
Via Benzinga
Aquestive Therapeutics Completes $45 Million Debt Refinancing
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reaffirms Timeline and Pathway for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Receives FDA Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film in Pediatric Patients and Assignment of Prescription Drug User Fee Act (PDUFA) Date
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in 2023 Wedbush PacGrow Healthcare Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Announces Positive Topline Pharmacokinetic Data for Anaphylm™ (epinephrine) Sublingual Film
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at Global Food Allergy Prevention Summit
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Reports Positive Results from Latest Clinical Studies Evaluating Pharmacokinetic and Pharmacodynamic Performance of Anaphylm ™ (epinephrine) Sublingual Film and Provides Findings from Recent Auto-Injector Clinical Study
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Aquestive Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics Receives Conditional FDA Acceptance of Proprietary Name Anaphylm™ for Lead Candidate AQST-109 (Epinephrine Sublingual Film)
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Aquestive Therapeutics to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 2 and Host Conference Call on May 3 at 8:00 a.m. ET
From Aquestive Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.